
Mattias Ekstedt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5072296/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease—A Systematic Review. Clinical Gastroenterology and Hepatology, 2023, 21, 283-298.	4.4	7
2	Risk for hepatic and extraâ€hepatic outcomes in nonalcoholic fatty liver disease. Journal of Internal Medicine, 2022, 292, 177-189.	6.0	11
3	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scandinavian Journal of Gastroenterology, 2022, 57, 60-69.	1.5	3
4	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
5	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 2022, 4, 100409.	4.9	20
6	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. Journal of Hepatology, 2022, 76, 1013-1020.	3.7	66
7	The paradigm shift from <scp>NAFLD</scp> to <scp>MAFLD</scp> : A global primary care viewpoint. Liver International, 2022, 42, 1259-1267.	3.9	15
8	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 1001-1012.	3.7	54
9	Repeated measurements of nonâ€invasive fibrosis tests to monitor the progression of nonâ€alcoholic fatty liver disease: A longâ€ŧerm followâ€up study. Liver International, 2022, 42, 1545-1556.	3.9	6
10	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	3.7	114
11	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2008-e2020.	3.6	27
12	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones, 2022, 21, 349-368.	1.9	12
13	Hepatic patatinâ€like phospholipase domainâ€containing 3 levels are increased in 1148M risk allele carriers and correlate with NAFLD in humans. Hepatology Communications, 2022, 6, 2689-2701.	4.3	5
14	"Considerations in the search for under-reported alcohol consumption in NAFLD― Journal of Hepatology, 2022, , .	3.7	2
15	Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2021, 115, 154439.	3.4	41
16	Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Reports, 2021, 3, 100197.	4.9	41
17	Morbidity, risk of cancer and mortality in 3645 <i>HFE</i> mutations carriers. Liver International, 2021, 41, 545-553.	3.9	11
18	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scandinavian Journal of Gastroenterology, 2021, 56, 437-442.	1.5	4

#	Article	IF	CITATIONS
19	A Dynamic Aspartateâ€toâ€Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. Hepatology Communications, 2021, 5, 1021-1035.	4.3	23
20	Reply to: "Rationale of adding muscle volume to muscle fat infiltration in the definition of an adverse muscle composition is unclear". JHEP Reports, 2021, 3, 100257.	4.9	1
21	European †NAFLD Preparedness Index' — Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	4.9	27
22	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. JHEP Reports, 2021, 3, 100218.	4.9	26
23	Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterology, 2021, 21, 180.	2.0	5
24	Low hepatic manganese concentrations in patients with hepatic steatosis – A cohort study of copper, iron and manganese in liver biopsies. Journal of Trace Elements in Medicine and Biology, 2021, 67, 126772.	3.0	15
25	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021, 75, 770-785.	3.7	149
26	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. Journal of Hepatology, 2020, 72, 14-24.	3.7	123
27	Cardiorespiratory fitness, muscular strength, and obesity in adolescence and later chronic disability due to cardiovascular disease: a cohort study of 1 million men. European Heart Journal, 2020, 41, 1503-1510.	2.2	68
28	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. Clinical Gastroenterology and Hepatology, 2020, 18, 1592-1599.e8.	4.4	21
29	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	1.8	71
30	Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scandinavian Journal of Gastroenterology, 2020, 55, 848-859.	1.5	15
31	Bariatric surgery versus standard obesity treatment and the risk of severe liver disease: Data from the Swedish Obese Subjects study. Clinical Gastroenterology and Hepatology, 2020, 19, 2675-2676.e2.	4.4	3
32	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Science Translational Medicine, 2020, 12, .	12.4	205
33	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism: Clinical and Experimental, 2020, 113, 154413.	3.4	45
34	Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients – A real life cohort study of two treatment strategies. IJC Heart and Vasculature, 2020, 27, 100495.	1.1	9
35	Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154183.	3.4	39
36	The amount of liver fat predicts mortality and development of type 2 diabetes in nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 1069-1078.	3.9	31

#	Article	IF	CITATIONS
37	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ~†. Journal of Hepatology, 2020, 73, 505-515.	3.7	279
38	Modifiers of Liver-Related Manifestation in the Course of NAFLD. Current Pharmaceutical Design, 2020, 26, 1062-1078.	1.9	8
39	Assessing the disease burden of non-alcoholic fatty liver disease in the real world – big data and big numbers. BMC Medicine, 2019, 17, 123.	5.5	4
40	Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort. PLoS Computational Biology, 2019, 15, e1007157.	3.2	6
41	Alcohol consumption in non-alcoholic fatty liver disease—harmful or beneficial?. Hepatobiliary Surgery and Nutrition, 2019, 8, 311-313.	1.5	3
42	Collagen proportionate area is an independent predictor of longâ€ŧerm outcome in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 1214-1222.	3.7	55
43	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1148-1156.e4.	4.4	71
44	PNPLA3 variant M148 causes resistance to starvationâ€mediated lipid droplet autophagy in human hepatocytes. Journal of Cellular Biochemistry, 2019, 120, 343-356.	2.6	44
45	Liver R2* is affected by both iron and fat: A dual biopsyâ€validated study of chronic liver disease. Journal of Magnetic Resonance Imaging, 2019, 50, 325-333.	3.4	22
46	Cardiovascular risk factors in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 197-204.	3.9	75
47	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A longâ€ŧerm followâ€up study. Hepatology Communications, 2018, 2, 48-57.	4.3	200
48	Natural history of nonalcoholic fatty liver disease: A prospective followâ€up study with serial biopsies. Hepatology Communications, 2018, 2, 199-210.	4.3	102
49	Bleeding complications after myocardial infarction in a real world population - An observational retrospective study with a sex perspective. Thrombosis Research, 2018, 167, 156-163.	1.7	6
50	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and metaâ€analysis. Hepatology, 2017, 65, 1557-1565.	7.3	1,294
51	Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. Gastroenterology, 2017, 153, 53-55.e7.	1.3	51
52	Collagen proportion area is an independent predictor of longterm outcome in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2017, 66, S52.	3.7	1
53	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology, 2017, 67, 1265-1273.	3.7	730
54	SAF score and mortality in NAFLD after up to 41 years of follow-up. Scandinavian Journal of Gastroenterology, 2017, 52, 87-91.	1.5	32

#	Article	IF	CITATIONS
55	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2017, 52, 159-165.	1.5	60
56	Automated quantification of steatosis: agreement with stereological point counting. Diagnostic Pathology, 2017, 12, 80.	2.0	15
57	Natural History of NAFLD/NASH. Current Hepatology Reports, 2017, 16, 391-397.	0.9	102
58	Reply. Hepatology, 2016, 64, 310-311.	7.3	0
59	Elevated serum ferritin is associated with increased mortality in nonâ€elcoholic fatty liver disease after 16 years of followâ€up. Liver International, 2016, 36, 1688-1695.	3.9	54
60	Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2016, 51, 1126-1132.	1.5	13
61	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS ONE, 2016, 11, e0167776.	2.5	17
62	Littoral Cell Angioma in a Patient with Crohn's Disease. Case Reports in Gastrointestinal Medicine, 2015, 2015, 1-4.	0.3	5
63	A Novel <i>SMAD4</i> Mutation Causing Severe Juvenile Polyposis Syndrome with Protein Losing Enteropathy, Immunodeficiency, and Hereditary Haemorrhagic Telangiectasia. Case Reports in Gastrointestinal Medicine, 2015, 2015, 1-5.	0.3	9
64	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. Translational Research, 2015, 165, 658-666.	5.0	28
65	Fibrosis stage is the strongest predictor for diseaseâ€specific mortality in NAFLD after up to 33 years of followâ€up. Hepatology, 2015, 61, 1547-1554.	7.3	1,683
66	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Medicine, 2014, 11, e1001680.	8.4	507
67	Pinworm Infestation Mimicking Crohns' Disease. Case Reports in Gastrointestinal Medicine, 2013, 2013, 1-4.	0.3	6
68	Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. Scandinavian Journal of Gastroenterology, 2012, 47, 108-115.	1.5	42
69	High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. Human Immunology, 2012, 73, 382-388.	2.4	25
70	Resistin is Associated with Breach of Tolerance and Antiâ€nuclear Antibodies in Patients with Hepatobiliary Inflammation. Scandinavian Journal of Immunology, 2011, 74, 463-470.	2.7	13
71	Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2009, 44, 366-374.	1.5	183
72	Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. European Journal of Radiology, 2008, 66, 313-320.	2.6	39

#	Article	IF	CITATIONS
73	Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. Journal of Hepatology, 2007, 47, 135-141.	3.7	242
74	Histological progression of nonâ€alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Alimentary Pharmacology and Therapeutics, 2007, 26, 821-830.	3.7	58
75	Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 2006, 44, 865-873.	7.3	2,038
76	Letter to the editor. Clinical Transplantation, 2005, 19, 571-571.	1.6	1
77	Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Modern Pathology, 2005, 18, 912-916.	5.5	100